Encouraging activity for R-CHOP in advanced stage nodular lymphocyte–predominant Hodgkin lymphoma

Nodular lymphocyte Hodgkin lymphoma (NLPHL) is a rare disease for which the optimal therapy is unknown. We hypothesized that rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) could decrease rates of relapse and transformation. We retrospectively reviewed patients wit...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Fanale, Michelle A., Cheah, Chan Yoon, Rich, Amy, Medeiros, L. Jeffrey, Lai, Chao-Ming, Oki, Yasuhiro, Romaguera, Jorge E., Fayad, Luis E., Hagemeister, F. B., Samaniego, Felipe, Rodriguez, Maria A., Neelapu, Sattva S., Lee, Hun J., Nastoupil, Loretta, Fowler, Nathan H., Turturro, Francesco, Westin, Jason R., Wang, Michael L., McLaughlin, Peter, Pinnix, Chelsea C., Milgrom, Sarah A., Dabaja, Bouthaina, Horowitz, Sandra B., Younes, Anas
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2017
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5578726/
https://ncbi.nlm.nih.gov/pubmed/28522441
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-02-766121
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars